Action 13
Committed by:
In pre-clinical and clinical development, initiate paediatric formulation development as soon as a given drug shows potential public health impact in adults, soon after Phase II trials are completed.
Pharmaceutical companies
Sub-Actions & Milestones
Sub-action 13.1

Initiate paediatric formulation development as soon as a given drug shows potential public health impact in adults, soon after Phase II trials are completed.

Pharmaceutical companies

ViiV will be increasing resources in Pediatrics further by appointing a Medicine Development Lead to span across the whole R&D portfolio to address these actions.

-

Milestone 13.1.1

Review ARV portfolio, prioritize PADO products and communicate changes with stakeholders

Pharmaceutical companies

-

-

Milestone. 13.1.2

Demonstrate timely implementation of PADO priorities as part of paediatric portfolio

Pharmaceutical companies

-

-

Updates

Notes

Responsible